

# MONTHLY UPDATE

December 2012

## Inside This Issue

- 1-2 Participation Opportunities  
IBA Lunch & Learn – Purchasing Benefits  
IBA 2013 Partnering For Growth Forum
- 2-4 New Member Spotlight  
BioScience Research Capital  
Brick Gentry PC  
Corvida Medical
- 4-7 Upcoming Events  
January 2013  
February 2013  
March 2013  
April 2013  
June 2013
- 8-9 Breaking News  
Food & Agriculture  
Healthcare & Pharmaceutical  
Industrial & Environmental
- 9-11 In Other News  
Rachel Hurley appointed to CSBA Board  
\$500,000 Available to Fund Internships in  
2013  
New Regulations Could be a Boon to Bio-Tech
- 11 Subscriber Information & Speaker  
Opportunities

## Participation Opportunities

[\(Return to Index\)](#)



### IBA Lunch & Learn – Office Supply Purchasing Agreement

[\(Return to Index\)](#)

Iowa Biotech Association is hosting a **FREE** Lunch & Learn on Tuesday, January 22, 2013 at the [BioVentures Center](#) in Coralville, Iowa. This event will take place from 11:30am-1:00pm with lunch provided.

This event will be the first in a series of meetings to help members and non-members alike to understand the purchasing benefits and discounts available to our members. Representatives from our current office supply vendor, OfficeMax, will be in attendance to answer any questions and discuss individual needs.

[To register for this event, please click here.](#) If you have any questions prior to the event, please contact us at [info@iowabio.org](mailto:info@iowabio.org).

###



### IBA Partnering For Growth Forum

[\(Return to Index\)](#)

In 2011, the Iowa Biotech Association (IBA) and the Iowa Innovation Corporation (IICORP) co-hosted the first installment of the Partnering For Growth Forum, a first-of-its-kind event in the state. This forum demonstrated a successful step in developing an ecosystem tasked with connecting “problem owners and solution providers”. The IBA, IICORP, Iowa State

# MONTHLY UPDATE

December 2012

University, the ag-biosciences business community and the USDA Agricultural Research Services (USDA-ARS) were brought together to connect Iowa businesses & entrepreneurs with commercially-relevant information and technology.

Many Iowa companies, ISU faculty and ARS scientists were connected through areas of mutual interest and requested the continuation of the conversation beyond the Forum. Thus, the real indicator of the Forum's success will come with time. The USDA-ARS leadership, ISU, IBA and the IICORP will work to track the output and outcomes of the nascent relationships hatched at the event and ask for previous guests' assistance by completing the [2011 RECAP SURVEY](#). With this information, the partner circle will be expanded with an eventual goal of bringing together multiple state and federal resources and Iowa companies, cross pollinating bioscience, advanced manufacturing and IT opportunities.

The Iowa Biotech Association and Iowa Innovation Corporation are excited to announce the second installment of this event. It is set to take place **March 27-28, 2012, and will once again be held at the FFA Enrichment Center on the DMACC Campus**. This event is **FREE** to attend and we welcome you to register as an Exhibiting Sponsor or a visiting guest. For more information, including registration details and pictures/presentations from 2011, [please click here](#). If you have any questions, please contact at (515) 327-9156 or by email at [info@iowabio.org](mailto:info@iowabio.org). We look forward to holding this event and seeing you there!

###

## New Member Spotlight

[\(Return to Index\)](#)



## BioScience Research Capital

[\(Return to Index\)](#)

BioScience Research Capital (BRC) is a life science consulting business founded in 2012 by Mahesh Mathrubutham, PhD, MBA and Tom Myers, CFA, MBA. BRC specializes in early stage product research and validation with businesses such as pharmaceuticals, nutraceuticals, medicinal foods and ingredients for humans, and companion animals. BRC also provides resources for identifying and analyzing market opportunities, developing customized solutions for new product line extensions. BRC also creates new marketing opportunities, licensing and other corporate partnering collaborations. BRC can help clients identify new growth opportunities that leverage their core mission, extend business capabilities, and move IP to new product and business initiatives from the bench to the market.

BRC can utilize its lab capabilities, industry research database, and market analysis skills, to establish new research initiatives and platforms to drive new products and future revenue. In addition, BRC can help clients find new uses and applications for their existing raw materials, intermediate and final products. With their combined experience in life sciences, finance and business analytics, BRC can evaluate the financial requirements and economic metrics of new capital spending, new product introductions, and new business directions. BRC can also help clients prioritize and develop ROI evaluation frameworks to determine short and long term business opportunities, while exploring unique ways to fund new growth through partnership, private equity and debt networks.

# MONTHLY UPDATE

December 2012

BRC's focus is to help clients grow their business in a profitable and strategically advantageous way. The Company's fee structure is aligned with their client's success. BRC offers a unique combination of expertise: Mahesh Mathrubutham's pharma, biotech and life science drug development and research experience, industry contacts, coupled with Tom Myers' business and financial analysis, valuation and strategic planning, marketing and capital markets expertise. Consulting with BRC would provide a dynamic complement to businesses with new developments in industries such as pharma, nutraceuticals, cosmeceuticals, food and cosmetic consumer products. BRC offers creative solutions to identify and develop opportunities for clients to leverage the value of their processes, products and IP.

For more information, please visit [www.bioscicap.com](http://www.bioscicap.com), or send a note to [info@bioscicap.com](mailto:info@bioscicap.com).

###



## Brick Gentry PC

[\(Return to Index\)](#)

Brick Gentry P.C. is a full-spectrum law firm, providing a broad range of legal services to businesses and individuals in practice areas including intellectual property, general business, healthcare, employment, municipal, family, debtor-creditor, litigation, and trust and estate law. Founded over 40 years ago on the principle of putting clients first, Brick Gentry P.C. is located in West Des Moines, Iowa and serves clients across the state and country.

The intellectual property lawyers at Brick Gentry combine their legal expertise and technical backgrounds to provide clients with the advice they need to protect their innovations consistent with their corporate objectives. Their subject matter expertise spans chemical and biological processes, mechanical, computer software and technology, and internet and

other business methods. In addition to preparing and filing patent and trademark applications, the firm provides availability, infringement, patent validity, and freedom to operate opinions. They also provide counsel regarding trade secrets, copyrights, mergers and acquisitions, and brand management, as well as represent clients in litigation matters.

Brick Gentry's business law team has expertise in areas including healthcare, employment and labor, real estate, and wills, trusts, and estates. The healthcare law team regularly represents physicians, physician groups and IPAs, and care facilities on specialized issues such as governance, contractual matters, and regulatory concerns. Moreover, the litigation group handles a full range of cases in both state and federal courts and before administrative agencies, with an emphasis on business-related litigation.

In addition to providing legal expertise, Brick Gentry sets itself apart by its commitment to create and maintain a lasting relationship with each client and understand the industry, goals and objectives of each client. Doing so allows the firm not only to provide counsel on the legal issue at hand, but also about the big picture impact of each decision.

Brick Gentry has committed to providing content for the Legal Section of the IBA website.

Brian J. Laurenzo, Shareholder and Registered Patent Attorney  
515-271-1748  
[brian.laurenzo@brickgentrylaw.com](mailto:brian.laurenzo@brickgentrylaw.com)  
[www.brickgentrylaw.com](http://www.brickgentrylaw.com)

###



## Corvida Medical

[\(Return to Index\)](#)

Corvida Medical is an emerging medical device manufacturing company headquartered at The

# MONTHLY UPDATE

December 2012

University of Iowa Research Park in Iowa City, IA and is committed to optimizing the safe handling of hazardous medications, such as chemotherapeutics used to treat cancer patients. The company was created after co-founder John Slump's sister was diagnosed with cancer, leading to the discovery that each year millions of healthcare workers are being routinely exposed to the hazardous pharmaceuticals prepared and administered to patients, significantly increasing risk for cancers, infertility, miscarriages, birth defects, genetic mutations, and other adverse events, according to OSHA, NIOSH, as well as other safety organizations and industry associations. While it has been well documented that significant occupational hazards confront healthcare workers that are responsible for compounding and administering drugs used in chemotherapy, products currently used to mitigate these risks suffer from drawbacks such as leakage, needle sticks, inaccuracies, inefficiencies, and repetitive stress injuries. As a result, long-term occupational exposure to these highly toxic drugs causes serious health problems in healthcare personnel. The innovative, disposable CSTD device being developed by Corvida Medical is designed to be a safeguard against these risks. Corvida Medical is passionately committed to creating innovative technologies enabling healthcare providers to safely deliver the highest quality care to their patients.

Corvida Medical was recently awarded a multi-million dollar Small Business Innovation Research (SBIR) Phase II follow-on grant from the National Cancer Institute (NCI) for their project entitled Innovative Device to Improve Safety of Preparing and Administering Chemotherapy. The NCI funding will be used to support the company's development of a disposable closed system transfer device (CSTD) for the preparation and administration of highly toxic pharmaceuticals such as chemotherapeutics used to treat cancer patients. The grant will help offset the costs of moving the company's product through the US Food and Drug Administration (FDA) clearance process and to conduct a multi-pharmacy practice trial with several leading U.S. cancer centers formally collaborating with the company on the promising SBIR NCI-funded project.

Corvida Medical also recently received the first-ever \$500,000 non-dilutive award from the Iowa Innovation Acceleration Program to help aid commercialization efforts. For more information about Corvida Medical, please contact John Slump, CFO/Co-Founder at [john.slump@corvidamedical.com](mailto:john.slump@corvidamedical.com) or (319) 335-2547 ext. 102.

###

## Upcoming Events

[\(Return to Index\)](#)

### [Biotech Showcase 2013](#)

January 7-9, 2013 / San Francisco, CA

Biotech Showcase provides innovative private and public life science companies the opportunity to present to an audience of investors and business development executives. More than 1,500 industry leaders will gather at Biotech Showcase during the week of the industry's largest annual healthcare investor conference. Qualified investors receive a complimentary registration at Biotech Showcase.

[\(Return to Index\)](#)



### [IBA BioProducts Committee Meeting](#)

January 15, 2013 / Des Moines, IA

IBA's BioProducts Committee is a consortium of industrial and academic innovators who utilize raw and composite renewable, recyclable, and biodegradable materials in commercial products and energy consumption. The committee's mission is to make Iowa a leader in biobased materials and be a leading resource for research, engineering, development, and production of bioproducts. The next meeting will take place in the IBA Boardroom from 2:00pm-4:00pm. To

# MONTHLY UPDATE

December 2012

review the upcoming meeting's agenda and register for the event, [please click here](#).  
([Return to Index](#))



## [Welcome Back Legislative Reception](#)

January 15, 2013 / Des Moines, IA

Consider this your "Save the Date" for the 2013 Welcome Back Legislative Reception! Similar to last January, this event will take place at the State Historical Building in Des Moines, Iowa. The event will be held from 5:00pm-7:00pm with refreshments provided. This is a great opportunity to make new connections and meet with elected officials. **To register for this event, [please click here](#).**  
([Return to Index](#))



## [IBA Lunch & Learn – Office Supplies](#)

January 22, 2013 / Coralville, IA

Iowa Biotech Association is hosting a **FREE** Lunch & Learn on Tuesday, January 22, 2013 at the [BioVentures Center](#) in Coralville, Iowa. This event will take place from 11:30am-1:00pm with lunch provided. This event will be the first in a series of meetings to help members and non-members alike to understand the purchasing benefits and discounts available to our members. Representatives from our current vendor, OfficeMax, will be in attendance to further answer any questions and discuss individual needs. **To register for this event, [please click here](#).**  
([Return to Index](#))

## [iExploreSTEM Festival](#)

January 26, 2013 / Des Moines, IA

iExploreSTEM is a series of coordinated free, hands-on, science, technology, engineering, and math (STEM) festivals that have the look and feel of a street fair or

county fair. Festival activities challenge children to think - to solve STEM problems – and introduce them to careers in STEM. They are designed so that regardless of abilities, all children succeed and have fun. Kids might design and build a windmill, dissect a virtual cadaver, or explore a career through video games.

Parents and children interact with the STEM professionals that staff the activities, allowing visitors to see that STEM professionals are "real people" and learn about the everyday realities of a STEM career.  
([Return to Index](#))

## [4<sup>th</sup> Annual Next Generation Bio-Based Chemicals Summit](#)

January 28-31, 2013 / San Diego, CA

At this event, strategists, financiers, business development officers, product stewards, and R&D directors from chemicals, bioplastics, consumer goods, and agribiz leaders from around the world will convene in San Diego for Infocast's Next Generation Bio-Based Chemicals Summit, the premier global deal-making hub for the sustainable chemicals industry.

This year's Summit will reflect the rapid growth of the bio-based space as many leading projects break ground on demonstration plants, as partnerships with brand owners and chemical majors proliferate, and start-ups connect across the value chain to develop innovative "greener/safer" applications and substitutes.  
([Return to Index](#))

## [Agribusiness Showcase & Conference](#)

February 12-13, 2013 / Des Moines, IA

The Agribusiness Showcase & Conference offers vendors and attendees the opportunity to explore the groundbreaking tools and ideas they need to grow their business, now and into the future. The industry's innovation and technology will be showcased through featured speakers, presentations and exhibitors. Over 1,000 progressive agricultural thinkers from Iowa and surrounding states are expected, which will include top crop production professionals, grain professionals,

# MONTHLY UPDATE

December 2012

pesticide and manure applicators, seed industry representatives and more. AAI staff and members have worked over the past year to improve the event in many ways which will benefit exhibitors and drive attendance even higher.

[\(Return to Index\)](#)

## [5th International Conference on Drug Discovery and Therapy](#)

February 18-21, 2013 / Dubai, UAE

This unique international conference provides a platform for all pharmaceutical scientists, internists and primary care physicians to discuss and learn about all the important international breakthrough developments in drug discovery and on new therapeutics. After the overwhelming success of the previous conferences held in Dubai in February 2008, 2010, 2011 and 2012 (where many Nobel Laureates attended), the fifth conference promises to be a much larger event with over 500 talks delivered and 40 thematic sessions with poster presentations and an associated commercial exhibition.

[\(Return to Index\)](#)

## [International Conference on Drug Development](#)

February 25-26, 2013 / Austin, TX

Register now for the 53rd Annual International Conference on Drug Development (ICD2) taking place in Austin Texas USA on February 25 & 26. Over 20 speakers and panels in two days offering the most informative and up to date information in science and regulation of global drug development. Registration fees include hotel accommodations, meals, and program.

[\(Return to Index\)](#)

## [2013 BIO Fly-In](#)

March 12-13, 2013 / Washington D.C.

Once a year, BIO hosts the Legislative Day Fly-In, inviting biotechnology executives from across the country to come to Washington D.C. for a day and a

half of legislative briefings and advocacy. BIO's 2013 Fly-In will occur March 12-13, 2013, and we are looking forward to another great day of engaging with Members of Congress and their senior staff on the most important legislative issues facing the biotechnology industry. BIO will schedule all congressional meetings and provide attendees with a robust legislative briefing prior to their visits on Capitol Hill. Attendees meet in small groups with the congressional Members and senior staff of the attendee's congressional delegation. Each group will be accompanied by a BIO staff representative to all visits.

**For more information regarding hotel accommodations, event agenda and registration, [please click here.](#)**

[\(Return to Index\)](#)

## [BIO's IP Counsels Committee Conference](#)

March 25-27, 2013 / San Diego, CA

For years, the BIO IP Counsels Committee has hosted the one-of-a-kind biannual BIO IPCC conference. Each year, the content is more compelling and the attendee list more extensive. BIO cordially invites you to attend the 2013 BIO IP Counsels Committee Spring Conference and Meeting in San Diego, California.

- Learn practical tips to tackle real issues
- Network with fellow IP professionals in the biotech industry.
- Discuss the ever-evolving patent system and the latest case law updates
- Meet experts in regulatory issues and litigation strategies

[\(Return to Index\)](#)

## [2013 Prometheus Awards](#)

April 9, 2013 / Des Moines, IA

The Technology Association of Iowa (TAI) and LWBj Financial will host the 8th annual Prometheus Awards on Tuesday, April 9th at Veterans Memorial Auditorium in Des Moines. The Prometheus Awards have been established as Iowa's largest and most prestigious distinction dedicated to recognizing and celebrating the innovation and brilliance of Iowa's high-tech industry. This ceremony honors both companies

# MONTHLY UPDATE

December 2012

and individuals who have demonstrated outstanding leadership and excellence in technology.

Technology companies, technology divisions of companies, and individuals doing business in Iowa are encouraged to apply. The majority of the work for which the application is submitted must be done in Iowa, and the majority of the team must be Iowa-based. **Nominations are due no later than Monday, January 28, 2013.**  
([Return to Index](#))

## [2013 International Society for Extracellular Vesicles](#)

April 17-21, 2013 / Boston, MA

The International Society for Extracellular Vesicles (ISEV) invites you to submit an abstract for their upcoming conference in Boston, Massachusetts. It is the hope to use the ISEV meeting as a focus for sessions devoted to exosomal (microvesicular) studies of pressing disease areas. Many of you have worked in these fields and appreciate the potential of microvesicles as diagnostic biomarkers, markers of tumor proliferation, targets for therapy, and for pathway analysis. To learn more about this rapidly growing sector of life science research, please follow the conference link below. You are encouraged to attend the meeting, regardless of your background, even if you do not submit an abstract.

<http://www.isevmeeting.org/>

**[ABSTRACT SUBMISSION DEADLINE IS JANUARY 20, 2012.](#)**

([Return to Index](#))

## [2013 BIO International Convention](#)

April 22-25, 2013 / Chicago, IL

More than 16,500 biotech leaders from 4,000 companies in 65 countries will gather at BIO to network and discuss issues shaping the industry, as well as visit with 2,000+ companies showcasing the latest technologies, products and services. BIO One-on-One Partnering™ makes it easy to find potential

partners and set up face-to-face meetings in the BIO Business Forum and the BIO Exhibition. There is a wide range of registration packages available to suit your specific needs and if you **register by March 14th, you'll save up to 25%.**

**Money Saving Opportunity!** - Domestic Trade Assistance Program (DTAP) funds are a great way to receive financial assistance to attend this event. Funds are limited so **[apply ASAP by clicking here.](#)** This link will provide you with instructions on how to apply, as well as other financial assistance opportunities such as the Export Trade Assistance Program and State Export Trade Assistance program.  
([Return to Index](#))

## [2013 BIO World Congress](#)

June 16-19, 2013 / Montréal, Canada

The BIO World Congress on Industrial Biotechnology is the world's largest industrial biotechnology event for business leaders, investors and policy makers in biofuels, biobased products, and renewable chemicals. Entering its tenth year, BIO World Congress offers unique networking opportunities, an overview of the latest technological developments and real world scenarios for bringing technological solutions to market. The event features discussions of high profile topics related to sustainability, new sources of fuel, climate change, financing, and policy.

**Money Saving Opportunity!** – Export Trade Assistance Program (ETAP) funds are a great way to receive financial assistance to attend this event. The application date has been extended to **September 30, 2013.** **[By clicking here,](#)** you will find information on how to apply, as well as on other financial assistance opportunities such as the Domestic Trade Assistance Program and State Export Trade Assistance program.  
([Return to Index](#))

###

# MONTHLY UPDATE

December 2012

## Breaking News

[\(Return to Index\)](#)

## Food & Agriculture

[\(Return to Index\)](#)



- ✔ **DuPont licenses Two Blades' sequencing technology**



- ✔ **EFSA supports safety of Monsanto's biotech maize pollen for food use**
- ✔ **Journal should retract French biotech corn study, experts say**
- ✔ **Genome-based cassava breeding effort gets \$25.2M boost**
- ✔ **Benson Hill Biosystems seeks to improve intrinsic crop yield**
- ✔ **Bayer, Syngenta seek Canadian approval for biotech soybean**
- ✔ **U.K. environment secretary supports adoption of biotech foods**
- ✔ **Rothamsted plans to proceed with biotech wheat studies**
- ✔ **EU-backed project will study drought-resistant crops**

###

## Healthcare & Pharmaceutical

[\(Return to Index\)](#)

### Genentech

- ✔ **Genentech readies for groundbreaking \$100M trial of Alzheimer's therapy**

### Johnson & Johnson

- ✔ **FDA expands approval for J&J's Zytiga drug**



- ✔ **GSK, MD Anderson unite to develop cancer drugs**
- ✔ **GSK partners with cancer center to develop muscular dystrophy drugs**



- ✔ **Pfizer Joins Personalized Cancer Medicine Consortium**



- ✔ **Amgen agrees to acquire deCODE Genetics for \$415M**
- ✔ **Supreme Court To Decide If Human Genes Can Be Patented In Myriad Case**
- ✔ **Can a Jellyfish Unlock the Secret of Immortality?**
- ✔ **Researchers grow blood vessels from personalized stem cells**
- ✔ **Vertex gets OK to market cystic fibrosis drug in Canada**
- ✔ **CureLab taps Aldevron to manufacture cancer vaccine**

# MONTHLY UPDATE

December 2012

- ❖ Study: 10 years of **AstraZeneca's Nolvadex** better to prevent cancer
- ❖ The **HIV Virus: A Possible Cure for Leukemia?**
- ❖ FDA's approval sought to use **biotech mosquitoes for dengue control**
- ❖ **Genomics investments** start to pay off
- ❖ Patient Shows New Dexterity with a **Mind-Controlled Robot Arm**
- ❖ Connecticut biotech raises \$10M for trials of **chronic itch treatment**
- ❖ **Gene therapy** may boost life expectancy in rare brain disorder
- ❖ **Brazilian agency** to build demonstration **cellulosic-ethanol plant**
- ❖ **NDSU** Awarded Funds to **Analyze Sugar Beets for Biofuel**
- ❖ **Cellulosic ethanol** could hit the market in 2013
- ❖ **Woodland Biofuels** moves closer to commercialization
- ❖ **Defense bill done:** biofuels survive
- ❖ House, Senate agree to **keep Defense Dept.'s biofuels program**

###

###

## Industrial & Environmental

[\(Return to Index\)](#)

- ❖ **DuPont** moves forward on **cellulosic-ethanol project in Iowa**
- ❖ **Fulcrum BioEnergy** secures \$175M in financing commitments for **1st MSW-to-biofuels project**
- ❖ **AAA** calls on EPA to **suspend sales of E15**
- ❖ Senate votes to allow **Defense Department to invest in biorefineries**
- ❖ Researchers get \$9.2M grant to study **biofuel potential of E. coli**
- ❖ EIA: **Biofuels** to account for 5.8% of **liquid-fuels market by 2040**

## In Other News...

[\(Return to Index\)](#)

### Rachel Hurley Appointed to CSBA Board

[\(Return to Index\)](#)

The Council of State Bioscience Associations (CSBA) is a confederation of state-based, non-profit trade organizations each governed by its own board of directors. The common mission of the members of the CSBA is to promote public understanding, and to advocate for public policies that support the responsible development of the bioscience industry.

During the recent Annual CSBA Conference, held November 26-28, several panel forums took place to further discuss the Council's mission, goals and needs. Several break-out events also took place, including a meeting with CSBA's Midwest

# MONTHLY UPDATE

December 2012

members. During this meeting, Rachel Hurley was appointed by her peers to be the Midwest Board Member for the Council. Rachel enthusiastically accepted the role and looks forward to representing the Midwest at future CSBA events.

###



## \$500,000 Available to Fund Internships in 2013

[\(Return to Index\)](#)

The goal of the **IEDA Student Internship Program** is to enlarge of the pool of talented workers for Iowa's businesses, create enriching student work experiences and assist students in obtaining permanent full-time employment in Iowa after graduation.

The Student Internship Program is a unique partnership of academia, industry and government all working together to link young Iowans to the state's unlimited career opportunities and help Iowa companies to recruit their future workforce.

Companies with fewer than 500 employees in the biosciences, advanced manufacturing and information technology industries are eligible for the program. The program provides grants up to \$3,100 per internship, up to a maximum of \$6,200 towards two internships per company. It's applicable for internships offered by eligible companies to students at any community college, private college or state university in Iowa.

**The deadline for the 2013 applications is April 30, 2013.**

More information is available on the IEDA web site [by clicking here](#).

The Program Manager and contact, Alana Anderson, can be contacted by phone at 515.725.3196 or email [alana.angerson@iowa.gov](mailto:alana.angerson@iowa.gov).

###

## New Regulations Could be a Boon to Bio-Tech

[\(Return to Index\)](#)

Original Article by Chris Metinko  
[View Original Article](#)

Could the 1990s surge of biotech investment be happening again?

With new legislation, mergers and IPOs all helping lead the way, the biotech industry is seeing levels of investment not seen in recent years.

Earlier this year, the industry gained notice with several big-name mergers and acquisitions, such as GlaxoSmithKline's acquisition of Human Genome Sciences for \$3 billion in August, and Spectrum Pharmaceuticals Inc.'s \$206 million purchase of Allos Therapeutics in April. There also has been a surge of new FDA approvals that have attracted investor attention--including a drug from Onyx Pharmaceuticals to treat a rare blood cancer and an obesity drug from VIVUS Inc.

On top of all that, an avalanche of IPOs have occurred in the industry since July, with companies such as Durata, Hyperion, Regulus, Kythera, and Intercept going public.

However, new legislation introduced on Capitol Hill could help bring the biggest boon to the industry.

# MONTHLY UPDATE

December 2012

The recently introduced High Technology Small Business Research Incentives Act would allow private investors in small biotech companies to use the losses of a research and development project as a tax benefit--exempting the investor from passive loss rules.

The bill would apply to entities that devote a significant percentage of their expenses to research and development, have fewer than 250 employees and have less than \$150 million in gross assets.

The bill, however, still has a long way to go before becoming law. In September it was referred to the House Committee on Ways and Means, but has not been considered by either bodies of Congress. Less than 2 percent of bills introduced in Congress in 2012 have been enacted.

###

## Subscriber Information

[\(Return to Index\)](#)

This message was sent to you as a benefit of membership in the IBA and/or a subscriber of our monthly newsletter. If you know of a company that would benefit from the Association's advocacy, financial savings and education/workforce focus, please have them contact the Association at 515-327-9156 or email [rachelhurley@iowabio.org](mailto:rachelhurley@iowabio.org). Membership details are also available at [www.iowabio.org](http://www.iowabio.org).

If you would like more information on any topic or no longer wish to receive these messages, please email [melissa@iowabio.org](mailto:melissa@iowabio.org) or call 515-494-9242.

## Speaker Opportunities

[\(Return to Index\)](#)

IBA staff members are available to give 15-60 minute speeches to interested groups, such as Rotary Clubs, trade associations, or civic groups. A broad range of topics could be discussed, included biotechnology, healthcare, food vs. fuel, legislative policy, investment and more. Contact Rachel Hurley at (515) 327-9156 or [rachelhurley@iowabio.org](mailto:rachelhurley@iowabio.org).